UI Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title
Phase II Study of Dose-Adjusted EPOCH+/-Rituximab in Adults with Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma

Participants in this study have been diagnosed with aggressive B-Cell lymphoma. The purpose of this research study is to compare the good and/or bad effects of an experimental approach to treating the disease. Approximately 9 people will take part in this study conducted by investigators at the University of Iowa. Involvement in the chemotherapy regimen, may last between 9 to 24 weeks. After completing the study treatment portion, the study doctor will ask participants to schedule follow-up exams for at least 5 years.

Start Date
January 17, 2013
End Date
January 17, 2023
Gender Preference
Age Group
18 - 99 years
Principal Investigator
Brian Link, MD
Contact Info

Clarine Halvorsen, 319-356-3944

b-cell lymphoma ; cancer ; chemotherapy ; IRB#201208728 ; link ; NCIMET trial #9177 ; phase II ; phase two ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.